The obesity epidemic: Why diets don't work

In an era where GLP-1 drugs promise sustained weight reduction for millions grappling with obesity and diabetes, the conversation has shifted from calorie counting to pharmaceutical intervention. Yet this moment raises urgent questions about whether such treatments address the underlying biology of weight or simply sidestep persistent societal and regulatory forces. Sandra Aamodt's analysis offers a timely lens on these tensions.

Speaker's Core Thesis

A neuroscientist, Aamodt details why traditional diets consistently fail by illuminating the biological mechanisms that regulate body weight. Her account emphasizes that these regulatory processes resist long-term change, even as external pressures around body image intensify health concerns. The talk explicitly connects these dynamics to emerging weight-loss drugs like Ozempic, framing them within broader societal and physiological contexts.

Reframing the Ozempic-Era Discussion

Aamodt's emphasis on biological drivers of weight reinforces the appeal of GLP-1 medications that act through appetite regulation, positioning them as tools potentially more aligned with the body's own controls than restrictive eating plans. At the same time, her focus on weight regulation complicates any assumption that pharmacological appetite suppression alone resolves the issue, since the underlying set points and feedback loops remain active. Societal pressures highlighted in the talk further reframe the topic by suggesting that drugs may alter individual outcomes without easing collective expectations around body size and health.

An Open Question

If these medications succeed in delivering weight loss where diets have not, readers must consider whether they truly engage the regulatory systems Aamodt describes or instead leave the deeper biological and social structures untouched, inviting closer scrutiny of what lasting health improvement requires.